- Home
- LAW vs CRDF Comparison
LAW vs CRDF Comparison
Compare LAW & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAW
- CRDF
- Stock Information
- Founded
- LAW 2013
- CRDF 1999
- Country
- LAW United States
- CRDF United States
- Employees
- LAW N/A
- CRDF N/A
- Industry
- LAW Computer Software: Prepackaged Software
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LAW Technology
- CRDF Health Care
- Exchange
- LAW Nasdaq
- CRDF Nasdaq
- Market Cap
- LAW 259.6M
- CRDF 233.5M
- IPO Year
- LAW 2021
- CRDF N/A
- Fundamental
- Price
- LAW $4.10
- CRDF $4.14
- Analyst Decision
- LAW Buy
- CRDF Strong Buy
- Analyst Count
- LAW 2
- CRDF 6
- Target Price
- LAW $6.75
- CRDF $11.92
- AVG Volume (30 Days)
- LAW 138.3K
- CRDF 1.5M
- Earning Date
- LAW 08-06-2025
- CRDF 08-07-2025
- Dividend Yield
- LAW N/A
- CRDF N/A
- EPS Growth
- LAW N/A
- CRDF N/A
- EPS
- LAW N/A
- CRDF N/A
- Revenue
- LAW $145,923,000.00
- CRDF $587,000.00
- Revenue This Year
- LAW $6.11
- CRDF N/A
- Revenue Next Year
- LAW $6.46
- CRDF N/A
- P/E Ratio
- LAW N/A
- CRDF N/A
- Revenue Growth
- LAW 3.84
- CRDF N/A
- 52 Week Low
- LAW $3.31
- CRDF $2.01
- 52 Week High
- LAW $6.64
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- LAW 45.31
- CRDF 56.71
- Support Level
- LAW $4.05
- CRDF $3.73
- Resistance Level
- LAW $4.21
- CRDF $4.56
- Average True Range (ATR)
- LAW 0.14
- CRDF 0.29
- MACD
- LAW -0.03
- CRDF -0.01
- Stochastic Oscillator
- LAW 21.31
- CRDF 53.85
About LAW CS Disco Inc.
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.